Hoffmann-La Roche: Pancreatic Neoplasms trials
The registry lists 16 Pancreatic Neoplasms studies with Hoffmann-La Roche as lead sponsor. 0 are open to participants now and 10 have results posted.
Phase 1 5Phase 2 7Phase 3 2Phase 4 1No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsTerminatedNCT04644315Phase 2Results posted
- A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid TumorsCompletedNCT02999672Phase 2Results posted
- A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic CancerCompletedNCT02694536Phase 3Results posted
- An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic CancerCompletedNCT01782690Results posted
- A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic CancerCompletedNCT01214720Phase 3Results posted
- ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic CancerCompletedNCT00925769Phase 1Results posted
- A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The PancreasCompletedNCT00711191Phase 1Results posted
- A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic CancerCompletedNCT00674973Phase 2Results posted
- A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic CancerCompletedNCT00652366Phase 2Results posted
- A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and SurvivalCompletedNCT00461708Phase 2Results posted
- P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid TumorsActive, not recruitingNCT05239143Phase 1
- Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)CompletedNCT02568267Phase 2
- A Study of Capecitabine (Xeloda) in Participants With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT02565641Phase 2
- A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic CancerCompletedNCT02146313Phase 1
- Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic CancerCompletedNCT01335958Phase 1
- A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic CancerTerminatedNCT00642733Phase 4